

# STIs: Practical Aspects of Management



Dr Heather Young FACHSHM DipPH

Christchurch Sexual Health

[heathery@xtra.co.nz](mailto:heathery@xtra.co.nz)

027 343 4963

# Sexually Transmitted Infections

- **BACTERIAL STIs:**
  - CHLAMYDIA
  - GONORRHOEA
  - SYPHILIS
  - Mycoplasma genitalium
- **PROTOZOAL STIs:**
  - Trichomonas
- **VIRAL STIs:**
  - HPV- warts
  - HSV – genital ulcers
  - Molluscum contagiosum
  - Hepatitis A,B,C
  - HIV
- **OTHER VAGINAL DISCHARGE SYNDROMES:**
  - Bacterial vaginosis
  - Candidiasis
  - Foreign bodies
  - (DIV)
- **INFESTATIONS:**
  - Scabies
  - Pubic lice
- **NOTIFIABLE STIs**
  - Congenital syphilis
  - Neonatal Gc eye infections
  - Acute hepatitis A,B,C
  - AIDS

# Epidemiology

# Public Health

$$R_0 = \beta \cdot c \cdot D$$

## $\beta$ (transmission)

VACCINATE  
Condoms  
Suppressive Rx  
nPEP  
STI cofactors  
Behaviour

## C (contact rate)

Sex education  
Moral restrictions  
Legality  
Venues  
Community devt

## D (duration)

Screening  
Health seeking  
Access  
Diagnosis  
Treatment  
Contact tracing

# **Primary Care-oriented resources**



The New Zealand  
Sexual Health Society

Thursday 9 to Saturday 11 September  
JAMES COOK HOTEL, WELLINGTON

32nd  
Annual  
Conference  
2010

OUR PAST,  
PRESENT  
AND  
FUTURE



# www.nzsh.org

NZSHS

Member Login

Home

Membership

Guidelines

Info sheets

Conferences

History

Links

Contact us

Legal

Sitemap

## Introduction

The New Zealand Sexual Health Society (NZSHS) Incorporated is a group of professionals working or interested in the field of Sexual Health. Membership is multidisciplinary and includes doctors, nurses, counsellors, educators, health promoters and others in Public Health working in the field of sexually transmissible infections, including HIV/AIDS, and sexual and reproductive health.

The New Zealand Sexual Health Society Inc. was formerly the New Zealand Venereological Society (NZVS). This change occurred in 2006 to more fully express the wider aims of this society.

The Society became Incorporated in April 2010.

Guidelines on the diagnosis and treatment of sexually transmitted infections can be found here as well as pdf's of presentations from our 2008 conference in Dunedin.

## Objectives of the society

- To advocate for and promote Sexual Health for all in New Zealand.
- To promote high standards of clinical practice within Sexual Health in New Zealand
- To promote the speciality of Sexual Health amongst colleagues and peers
- To encourage research within New Zealand with regard to Sexually Transmissible Infections (STIs).

The Society organises an annual conference, which includes an Annual General Meeting (AGM) and an academic programme. The Society's executive committee is elected at the AGM. Members must be financial to participate in the AGM or at Special General Meetings.

## Activities

- Promoting STI/HIV prevention and Sexual Health for all through education
- Acting as advocates for those most at risk of STIs and HIV/AIDS
- Ongoing central lobbying to ensure an continued commitment to the tenets of Sexual Health including free, confidential and widely available specialist clinical services
- Regular education forums for health professionals to provide ongoing education and support
- Advisory role to the Ministry of Health and other government agencies in relation to proposed legislative or policy changes affecting Sexual Health
- Monitoring the epidemiology of STIs and HIV/AIDS, and hence lobbying for appropriate intervention strategies
- Promoting the implementation of health education programmes
- Promoting the development of national guidelines for STI management
- Informing and updating NZSHS members through the NZSHS Bulletin

[www.herpes.org.nz](http://www.herpes.org.nz)

NEW ZEALAND HERPES FOUNDATION



**Guidelines for the  
Management of  
Genital Herpes  
in New Zealand**

9th Edition - 2009

Produced by the Professional Advisory Board (PAB) of the  
Viral Sexually Transmitted Infection Education Foundation



**HPV**

AUSTRALIA AND NEW ZEALAND  
HPV PROJECT

The New Zealand HPV Project

## **Guidelines for the Management of Genital HPV in New Zealand**

6th Edition - 2010

Produced by the Professional Advisory Board (PAB)  
of the New Zealand HPV Project

[www.hpv.org.nz](http://www.hpv.org.nz)



# General Practitioners and HIV

This supplement incorporates recommendations of the National HIV Testing Policy, 2006

## Introduction

The manifestations of human immunodeficiency virus (HIV) first became apparent in the early 1980s with reports of an epidemic of unexplained cases of immunodeficiency, first in the United States of America (USA) and then elsewhere in the Western world. Epidemiological evidence suggested that the cause was transmissible through sexual or blood contact or both, and in 1984 the agent was identified as a retrovirus which is now known as HIV.

In Australia, by the end of 2006, 26 330 new diagnoses of HIV infection had been notified since the start of the epidemic. In addition to 10 348 cases of acquired immunodeficiency syndrome (AIDS) and 6765 AIDS-related deaths. The prevalence of HIV infection is highest in men who have sex with men (MSM) in Australia. There is a very low prevalence of HIV infection in Australia in those whose only risk behaviour is heterosexual contact compared to many countries in the Asia-Pacific region. Hence, the risk of HIV infection occurring through heterosexual contact or sexual assault in Australia is low compared to that in high HIV prevalence countries, though it does still occur.

Early diagnosis of patients with HIV infection allows regular monitoring and timely intervention in terms of therapy when required which may markedly alter the natural history of HIV infection. Knowledge of the clinical signs and symptoms of primary HIV infection, as well as performing HIV testing with consent when appropriate, enable earlier HIV diagnosis by clinicians and provide patients with opportunities for receiving

appropriate referral, support and education on transmission prevention, in addition to therapy when required.


## The Virus

HIV is a single-stranded ribonucleic acid (RNA) virus. It has an outer envelope that surrounds two copies of single-stranded RNA as well as a number of viral proteins. The HIV replication commences when the envelope 120 glycoprotein (gp 120) attaches to CD4 receptors expressed on the surface of lymphocytes. Attachment allows fusion of the membranes of virus and cell at viral entry. The RNA is converted to deoxyribonucleic acid (DNA) which migrates to the cell nucleus and integrates as proviral DNA into the host cell DNA.

## Natural History

Following infection with HIV, there is a period of high-level viraemia associated with a reduction in the CD4 cell count. A host immune response then develops, partially controlling viral replication, but is unable to clear HIV from the body. The majority of patients develop a mononucleosis-like HIV seroconversion illness characterised by fever, pharyngitis, lymphadenopathy, rash, splenomegaly and aseptic meningitis. Other patients with HIV infection may either be asymptomatic or have subclinical illness. Symptoms of acute infection resolve as the immune system mounts an antiviral response that causes the viral load to decrease markedly. Simultaneously, there

FIGURE 1 HIV Natural History



MAC: Mycobacterium avium complex; CMV: cytomegalovirus; TS: Kaposi sarcoma; PJP: Pneumocystis jirovecii pneumonia; TB: tuberculosis  
 FIGURE 1 The various stages of HIV infection depicting the development of different opportunistic infections with advanced immunodeficiency and the impact of antiretroviral therapy on CD4 cell count recovery.

[www.ashm.org.au](http://www.ashm.org.au)

all you wanted  
to know about  
hepatitis B



Positive



# BEST PRACTICE

25

DECEMBER 2009



Infectious gastroenteritis  
Generalised anxiety disorder  
HIV  
Smoking associated cancers

# Other resources


- NZ Doctor: Sexual Health Column
- Doctors for Sexual Abuse Care: Management of sexual assault manual, training + publications
- Ministry of Health website: HIV testing
- Sexual Health Clinics
- Infectious Diseases/Microbiology

# All STIs

- Treat empirically in symptomatic individuals
- Advise abstinence until client + partner/s completed Rx
- Provide condoms
- Contact trace
- RESCREEN at epidemiologic interval (3 months)
- Do NOT do tests of cure unless pregnant\*
- A sexual health screen includes blood tests for HBV (Ab and Ag), syphilis and HIV +/- others as appropriate

# Chlamydia: Emergent Trends

- Azithromycin is safe throughout pregnancy
- Opportunistically screen all clients <25 yrs with a female low vaginal swab or male FVU
- Treat ANY lower abdominal pain as PID with 14 days of Chlamydia, GC + anaerobic antibiotic cover (syndromic Rx)
- Treat rectal chlamydia with doxycycline and \*do a TOC as LGV proctitis has appeared in NZ
- Adult chlamydial conjunctivitis can now be treated with a single stat dose of azithromycin



## DISEASES COMMONLY ASSOCIATED WITH SEROTYPES OF C. TRACHOMATIS

SEROTYPE	DISEASE
A, B, Ba, C	Endemic trachoma
B, D-K	Genitourinary disease
L1, L2, L3	LGV

- LGV has emerged as an “anorectal syndrome” in MSMs (as opposed to the classic inguinal syndrome)
- This usually presents as an acute proctitis but some cases may be asymptomatic or mildly symptomatic

# Chlamydia: The Future


- Variant strain nvCT emerged in Sweden 2006
- Arrested immunity hypothesis? Unproven
- Vaccine? A long way off
- New laboratory tests – eg genotyping for LGV
- Push for integrated antenatal screening guidelines!!!

(140 cases of Chlamydia and 6 cases gonorrhoea reported in infants < 1 year in 2009)

# Gonorrhoea: Emergent Trends

- Ceftriaxone is now first line treatment for gonorrhoea

Figure 14. Prevalence of penicillin and ciprofloxacin resistance among *N. gonorrhoeae*, 2000 to 2008





# Syphilis: Emergent Trends

- Infectious syphilis has risen ++ in NZ amongst MSMs with a secondary rise in the heterosexual population both from sex overseas and now within NZ
- The majority is in Auckland + Wgtn + ChCh
- Oral route of infection is emerging as important, age > 40 years, European ethnicity
- HIV coinfection is increasingly common
- Urgent enhanced surveillance is required
- Refer for advice
- Repeatedly screen HIV+ve individuals

# NSU

Urethritis  
Syndromic/lab criteria

Gonorrhoea

NGU

Chlamydia  
(Age dependent risk)

NSU

Mycoplasma genitalium

Oral/rectal organisms

Viral/protozoal/fungal  
UTI/Non STI causes

Persistent NSU occurs in 10-20%

Any treatment of persistent NGU should cover *T vaginalis*  
and *M genitalium*

First line treatment for persistent /recurrent NGU is  
Azithromycin 500mg stat, then 250mg daily for next 4 days  
plus  
Metronidazole 400mg twice daily for 5 days

# Contact Tracing

- Patient (index case referral)
- Provider referral

# Other Strategies

- Patient-delivered testing
- Patient-delivered treatment
- Presumptive treatment

## AUSTRALASIAN CONTACT TRACING MANUAL

A practical handbook for health care providers managing people with HIV, viral hepatitis, other sexually transmissible infections (STIs) and HIV-related tuberculosis.




EDITION 3 2006

# Summary

- For patient referral method provision of written material (contact sheets) and basic skills training is preferred
- Have a check in place to ensure partner/s attendance
- Treat contacts **IRRESPECTIVE** of negative test results
- Text messaging services are acceptable to adolescents
- The legality of PDPT is not established, so caution
- For provider referral utilise health advisors/public health

# Useful Clinical Algorithm



**Thank you**

**Acknowledgements**

**Dr Edward Coughlan**



Be a virus, see the world.